Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I.

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months ...

The co-antibody therapy JNJ-4804 -- a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) -- showed clinically meaningful efficacy exceeding that of either drug alone in patients ...

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or ...

Refractory metals are a class of metallic materials that offer superior heat resistance and very high melting points. While the exact definition of which elements are included in this group varies, ...

On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...

Promising trial results: AlloNK plus rituximab achieved a 71% ACR50 response rate in mid-stage testing for refractory rheumatoid arthritis, with no treatment-related serious adverse events. Regulatory ...

Global Refractory Material Market Global Refractory Material Market Dublin, April 08, 2022 (GLOBE NEWSWIRE) -- The "Refractory Material Market by form, Chemical Composition, Chemistry and End Use: ...

Elranatamab (Elrexfio; Pfizer) achieved the primary endpoint of progression-free survival (PFS) at a prespecified interim ...

Eptinezumab is associated with modest reductions in headache frequency for patients with chronic migraine with inadequate ...